Clinical trial · Interventional
PHA-739358 for Treatment of Hormone Refractory Prostate Cancer
A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer
NCT00766324CI-TRIAL-00014721completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Hormone Refractory Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PHA-739358 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- A
- interventionNames
- Drug: PHA-739358
- type
- EXPERIMENTAL
- label
- B
- interventionNames
- Drug: PHA-739358
Primary outcomes (1)
- measure
- PSA response rate defined according to the recommendations from the Prostate-Specific Antigen Working Group
- timeFrame
- within the first three months of treatment
Secondary outcomes (2)
- measure
- Objective Response Rate, Progression Free Survival, additional PSA based endpoints, clinical benefit
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic hormone refractory prostate cancer progressing after docetaxel based therapy * Adequate bone marrow, liver and kidney function Exclusion Criteria: * More than one prior chemotherapy line * Uncontrolled hypertension * Brain or leptomeningeal disease * Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months
References
Publications (0)
Data not yet available
No reference posted for this study.